HomeAI · summaries
Storia in 2 fonti
Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
- ·
biopharmadive.com
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.